NICE does not recommend Tecentriq for patients who have already received prior treatment for metastatic urothelial cancer. whose disease has progressed after platinum-based chemotherapy.- Roche.

In draft guidelines, the National Institute for Health and Care Excellence (NICE) notes that treatment options for patients with metastatic urothelial cancer, whose disease has progressed after platinum-based chemotherapy including docetaxel, paclitaxel or best supportive care, and that evidence from two clinical trials suggests that atezolizumab is an effective therapy.

However the cost of Tecentriq (atezolizumab) �is very high relative to the benefits it provides,� NICE said, and also highlighted �uncertainties in the economic model�, including how long people take the drug for and its long-term benefits. Tecentriq does meet NICE�s criteria to be considered a life-extending treatment at the end of life, but the most plausible cost-effectiveness estimate is much higher than what the Institute normally considers acceptable for end-of-life treatments and so it is not recommended for routine use in the NHS.